Clinical Trial

A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes

Study acronym: ENLIGHTEN-1
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the efficacy and safety of eloralintide in adults with obesity or overweight who do not have type 2 diabetes. The study has two phases: a main phase and an extension phase. Participation in the main phase of the study will last about 75 weeks. Participants with prediabetes will continue in the extension phase for another 2 years.
Protocol Amendment History 1 change
notable Trial sites reduced: 169 -> 162 locations 2026-07-19
Trial Details
NCT Number NCT07321886
Lead Sponsor Eli Lilly and Company
Conditions Obesity, Overweight
Enrollment 1,980 participants
Start Date 2026-02-06
Primary Completion 2028-03 (estimated)
Study Completion 2030-07 (estimated)
Updated on ClinicalTrials.gov 2026-07-17